1 / 29

MOPA-7: Useful Tool for Vaccine Monitoring

MOPA-7 is a valuable method to monitor the opsonophagocytosis activity against 7-valent conjugate vaccine serotypes. It measures immune-protective potential and aids in vaccine evaluation.

keilah
Download Presentation

MOPA-7: Useful Tool for Vaccine Monitoring

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. MOPA-7a useful tool to monitor the 7-valent pneumococcal conjugate vaccineP.W.M. HermansDepartment of PediatricsUniversity Medical Center St. RadboudNijmegen, The Netherlands

  2. Pediatrics UMC St. Radboud Nijmegen Pediatrics Erasmus MC Rotterdam

  3. Surface-associated proteome of S. pneumoniae - SB-14 fractioning - pI 4 7 200 97 68 43 Mr (kDa) 29 18 14 Overweg, 2000

  4. Surface-associated proteome of S. pneumoniae - SB-14 fractioning - pI 4 7 200 Mass spectrometry 97 68 43 Mr (kDa) 29 18 14 Overweg, 2000

  5. Surface-associated proteome of S. pneumoniae - SB-14 fractioning - pI 4 7 200 Mass spectrometry 97 68 43 Mr (kDa) PpmA 29 18 Antigen characterization 14 Overweg, 2000

  6. FITC-labeling opsonisation phagocytosis determine percentage FITC+ PMNs Immune-protective potentials: phagocytosis assay Overweg, 2000

  7. Immune-protective potentials: phagocytosis assay α –surface protein fraction α –PpmA Overweg, 2000

  8. Effect of a pneumococcal conjugate vaccine on recurrent otitis media • Dutch OMAVAX study • R. Veenhoven, Haarlem Pediatrics, Haarlem Pediatrics, Utrecht Pediatrics, Rotterdam

  9. MOPA-7a useful tool to monitor the 7-valent pneumococcal conjugate vaccine Bogaert et al.; Vaccine; 2004; 22: 4014-4020

  10. MOPA-7: strains

  11. MOPA-7: strains . . Origin clinical R-cassette clinical natural clinical natural clinical isolate isolate selection isolate selection isolate [Antibiotic] 1.0 4.0 16 400 1.5 400 32 (mg/L)

  12. MOPA-7: materials Serum: * two-fold serial dilutions in RPMI-1640 * dilution range 2 to 128 * 30 μl per microtiter well

  13. MOPA-7: materials Serum: * two-fold serial dilutions in RPMI-1640 * dilution range 2 to 128 * 30 μl per microtiter well Bacteria: * mixture of 7 serotypes (early-log cultures) in RPMI-1640 (1x washing) * 2x105 CFU/ml for each serotype * 15 μl per microtiter well

  14. MOPA-7: materials Serum: * two-fold serial dilutions in RPMI-1640 * dilution range 2 to 128 * 30 μl per microtiter well Bacteria: * mixture of 7 serotypes (early-log cultures) in RPMI-1640 (1x washing) * 2x105 CFU/ml for each serotype * 15 μl per microtiter well HL-60: * culture in RPMI-1640 / 10% FCS / 1 % Pen-Strep * differentiation in RPMI-1640 / 0.8% DMF (7 days) * renewal of medium at day 5 * 1.4x108 cells/ml RPMI-1640 / FCS (2x washing) * 60 μl per microtiter well

  15. MOPA-7: materials Serum: * two-fold serial dilutions in RPMI-1640 * dilution range 2 to 128 * 30 μl per microtiter well Bacteria: * mixture of 7 serotypes (early-log cultures) in RPMI-1640 (1x washing) * 2x105 CFU/ml for each serotype * 15 μl per microtiter well HL-60: * culture in RPMI-1640 / 10% FCS / 1 % Pen-Strep * differentiation in RPMI-1640 / 0.8% DMF (7 days) * renewal of medium at day 5 * 1.4x108 cells/ml RPMI-1640 / FCS (2x washing) * 60 μl per microtiter well Complement: * rabbit-derived *15 μl per microtiter well

  16. MOPA-7: methods • * Mix bacterial mix and diluted serum • * Incubate for 20 min at 37 0C

  17. MOPA-7: methods • * Mix bacterial mix and diluted serum • * Incubate for 20 min at 37 0C • 2. * Add HL-60 cells and complement (ratio bacteria : HL-60 = 1 : 400) • * Incubate for 1 hour at 37 0C

  18. MOPA-7: methods • * Mix bacterial mix and diluted serum • * Incubate for 20 min at 37 0C • 2. * Add HL-60 cells and complement (ratio bacteria : HL-60 = 1 : 400) • * Incubate for 1 hour at 37 0C • * Spot 10 μl on omnitray containing blood agar / antibiotic (MOPA) • * Plate 10 μl on plate containing blood agar / antibiotic (MSOPKA) • * Incubate overnight at 37 0C (reduced O2)

  19. MOPA-7: methods • * Mix bacterial mix and diluted serum • * Incubate for 20 min at 37 0C • 2. * Add HL-60 cells and complement (ratio bacteria : HL-60 = 1 : 400) • * Incubate for 1 hour at 37 0C • * Spot 10 μl on omnitray containing blood agar / antibiotic (MOPA) • * Plate 10 μl on plate containing blood agar / antibiotic (MSOPKA) • * Incubate overnight at 37 0C (reduced O2) • * Read out: MOPA titer is the reciprocal of the highest serum dilution with 90% killing as compared with the number of bacteria in the control experiment (bacteria / HL-60 / complement) • (MSOPKA: 50% killing)

  20. Capsular IgG ELISA

  21. Bacterial dilutions Controls Vaccinees Dilution MOPA titer 1:16 16 1:32 32 1:64 64 1:128 128 1:256 256 1:512 512 1:1024 1024 1. 2. 3 4. 5. 6. 1. 2. 3. + - 1:2 1:4 1:8 1:16 MOPA-7: example 23F (Tmp-R)

  22. Bacterial dilutions Controls Vaccinees Dilution MOPA titer 1:16 16 1:32 32 1:64 64 1:128 128 1:256 256 1:512 512 1:1024 1024 1. 2. 3 4. 5. 6. 1. 2. 3. + - 1:2 1:4 1:8 1:16 MOPA-7: example 23F (Tmp-R)

  23. MOPA-7: comparison with MSOPKA

  24. MOPA-7: comparison with MSOPKA (scatter plot) Best fit line for all serotypes: logMOPA = 0.86(logMSOPKA)+0.3; R-value (Pearson): 0.94 (p<0.001)

  25. MOPA-7: In conclusion MOPA-7 allows the simultaneous (‘high’ throughput) measurement of the opsonophagocytosis activity of serum against the capsular serotypes included in the 7-valent conjugate vaccine

  26. MOPA-7: In conclusion MOPA-7 allows the simultaneous (‘high’ throughput) measurement of the opsonophagocytosis activity of serum against the capsular serotypes included in the 7-valent conjugate vaccine MOPA-7 uses limited serum volumes (30 μl)

  27. MOPA-7: In conclusion MOPA-7 allows the simultaneous (‘high’ throughput) measurement of the opsonophagocytosis activity of serum against the capsular serotypes included in the 7-valent conjugate vaccine MOPA-7 uses limited serum volumes (30 μl) Data obtained with MOPA-7 correlate well with MSOPKA

  28. MOPA-7: In conclusion MOPA-7 allows the simultaneous (‘high’ throughput) measurement of the opsonophagocytosis activity of serum against the capsular serotypes included in the 7-valent conjugate vaccine MOPA-7 uses limited serum volumes (30 μl) Data obtained with MOPA-7 correlate well with MSOPKA Inter-laboratory standardization and multi-laboratory evaluation is requested!

More Related